Cooley Advises Underwriters on Eleven Biotherapeutics IPO

Reston, VA. – February 14, 2014 – Cooley LLP announced today that it advised the underwriters on the initial public offering of Eleven Biotherapeutics. A clinical-stage biopharmaceutical company, Eleven Biotherapeutics now trades on the NASDAQ Global Market under the symbol "EBIO."

Citigroup, Cowen and Company, LLC and Leerink Partners LLC acted as joint book-running managers for the offering.

The Cooley corporate and securities team advising the underwriters was led by partner Brent Siler and included partner Drew Williamson, special counsel Brian Leaf and associate Robert E. Jones. Critical support for the offering was provided by partner and chair of Cooley's healthcare and life sciences practice Drew Gantt, partner Natasha Leskovsek and associate David Sclar (regulatory); partner Bill Christiansen and associate Aaron Nudelman (intellectual property); and partner Susan Cooper Philpot (tax).

This offering follows Cooley's record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 20 public offerings, including 10 IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Susan Cooper Philpot Retired Partner, San Francisco
Brian Leaf Partner, Reston
Brent Siler Partner, Washington, DC
Natasha Leskovsek Partner, Washington, DC
Bill Christiansen Partner, Seattle
Drew Williamson Partner, San Francisco
Aaron Nudelman Associate, Seattle